Biogen (BIIB) partners with Alloy Therapeutics for antisense oligonucleotide platform access. RBC cuts price target to $213 while maintaining Outperform.

Biogen (BIIB) shares recorded their fifth consecutive day of increases, accumulating a total return of 14% during this span. The company’s market value has increased by approximately $3.3 billion over ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Markets are tanking on tariff fears, inflationary ...

Apellis Pharmaceuticals (APLS) shares soared on Tuesday after Biogen (BIIB) signed a definitive agreement to acquire the ...

Market positioning reflects broader sentiment shifts aligned with nasdaq composite movements.

Leqembi efficacy doubts in APOE4 subgroups raise regulatory and commercial risks for Eisai and Biogen; see real-world data ...

We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. On December 10, TheFly reported that HSBC downgraded BIIB from Hold to Reduce, and lowered its price target to $143, ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the January 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the May 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...